Drugs / CEP
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07046182 Background | Oct 2023 → May 2028 expected | angioimmunoblastic T-cell lymphoma | Zhengzhou University | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07046182 ↗ |